Literature DB >> 10525133

Effect of 17-beta estradiol on pre-existing atherosclerotic lesions: role of the endothelium.

H Hanke1, J Kamenz, S Hanke, J Spiess, C Lenz, U Brehme, B Bruck, G Finking, V Hombach.   

Abstract

The atheroprotective effects of estrogen during the process of atherogenesis is well documented, whereas limited information is available about the effect of estrogen on pre-existing atherosclerotic lesions. After bilateral ovariectomy, 24 New Zealand White rabbits were randomized into three groups of eight animals each and subsequently fed a 0.5% cholesterol diet. In group I, the vessels were excised at day 84, whereas in group II, the cholesterol diet was continued for a total of 168 days. In group III, the animals were first fed with a cholesterol diet for 84 days; in the second phase of the experiment, the cholesterol diet was continued for a further 84 days with a combined estrogen treatment (1 mg estradiol valerate per kg body weight per week intramuscularly). At the end of the experiment, the proximal aortic arch, right carotid artery, thoracical aorta and abdominal aorta of each animal were excised and prepared for histological and immunohistological examination. By day 168, morphometrical analysis displayed a significantly lower plaque development under estrogen therapy in the carotid artery (0.08+/-0.18 mm(2) vs. 0.60+/-0.39 mm(2)), the thoracic aorta (0.56+/-0.94 mm(2) vs. 3.63+/-2.06 mm(2)), and in the abdominal aorta (0.55+/-0.70 mm(2) vs. 1.71+/-1.05 mm(2)) in comparison with the corresponding 168 day control group. However, estrogen treatment has failed to reduce further atherosclerotic plaque development in the aortic arch (9.42+/-1.79 mm(2) vs. 11. 64+/-3.29 mm(2)). Immunohistological detection of the 'anti-human factor VIII related antigen', i.e. the 'von Willebrand factor' (vWF), showed a significantly lower number of luminal cells positive for vWF in the aortic arch in the 84-day cholesterol group, compared with the corresponding controls of normocholesterolemic rabbits (65. 9+/-12.4% vs. 83.1+/-6.2%; P<0.05). Estradiol was able to inhibit the further progression of atherosclerosis when moderate vessel wall alterations were present, whereas pre-existing severe atherosclerosis was associated with a failure of the anti-atherosclerotic estrogen action. As suggested by the in situ detection of vWF as a morphological marker for endothelial cells, an intact endothelial layer might play an important role in mediating the beneficial effect of estrogen in the process of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525133     DOI: 10.1016/s0021-9150(99)00182-3

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

Review 1.  The Women's Health Initiative study: perspectives and implications for clinical practice.

Authors:  Charles B Hammond
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

2.  Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy.

Authors:  Victor W Henderson; Roberta Diaz Brinton
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

3.  Hormone Therapy Use and Risk of Chronic Disease in the Nurses' Health Study: A Comparative Analysis With the Women's Health Initiative.

Authors:  Shilpa N Bhupathiraju; Francine Grodstein; Bernard A Rosner; Meir J Stampfer; Frank B Hu; Walter C Willett; JoAnn E Manson
Journal:  Am J Epidemiol       Date:  2017-09-15       Impact factor: 4.897

Review 4.  Oestrogen, atherosclerosis and cardiovascular disease in women: Epidemiological studies on menopause and hormone replacement therapy.

Authors:  I C D Westendorp; D E Grobbee; J C M Witteman
Journal:  Neth Heart J       Date:  2001-08       Impact factor: 2.380

Review 5.  Cardiovascular risk in menopausal women and our evolving understanding of menopausal hormone therapy: risks, benefits, and current guidelines for use.

Authors:  Sindhu Prabakaran; Arielle Schwartz; Gina Lundberg
Journal:  Ther Adv Endocrinol Metab       Date:  2021-04-30       Impact factor: 3.565

Review 6.  Estrogen Receptor and Vascular Aging.

Authors:  Morgane Davezac; Melissa Buscato; Rana Zahreddine; Patrick Lacolley; Daniel Henrion; Francoise Lenfant; Jean-Francois Arnal; Coralie Fontaine
Journal:  Front Aging       Date:  2021-09-24

7.  17beta-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice.

Authors:  Amparo C Villablanca; Amy Tenwolde; Michael Lee; Melissa Huck; Shannon Mumenthaler; John C Rutledge
Journal:  J Cardiovasc Transl Res       Date:  2009-05-02       Impact factor: 4.132

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.